Celera Genomics (NYSE:CRA), an Applera Corporation

Celera Genomics (NYSE:CRA), an Applera Corporation business, today announced that the National Institutes of Health (NIH) has awarded Celera approximately $900,000 to develop and commercialize an in vitro diagnostic (IVD) test for the highly pathogenic influenza A/H5 virus (Asian lineage, H5N1).

Research Published in Human Molecular Genetics and

Celera Genomics, an Applera Corporation business, and Medarex have formed a strategic collaboration to discover and develop fully human antibodies for the potential treatment of multiple cancer indications.

ROCKVILLE, Md. and PRINCETON, N.J., June 22 /PRNewswire-FirstCall/ -- Celera Genomics , an Applera Corporation business, and Medarex, Inc.